RGEN logo

RGEN
Repligen Corp.

1,554
Mkt Cap
$6.04B
Volume
1.04M
52W High
$175.77
52W Low
$106.92
PE Ratio
117.82
RGEN Fundamentals
Price
$101.48
Prev Close
$107.03
Open
$106.88
50D MA
$119.70
Beta
1.48
Avg. Volume
965,769.13
EPS (Annual)
$0.8644
P/B
2.87
Rev/Employee
$369,128.00
$9,190.41
Loading...
Loading...
News
all
press releases
JPMorgan Chase & Co. Lowers Repligen (NASDAQ:RGEN) Price Target to $165.00
JPMorgan Chase & Co. dropped their target price on Repligen from $180.00 to $165.00 and set an "overweight" rating for the company in a research report on Wednesday...
MarketBeat·8d ago
News Placeholder
More News
News Placeholder
Repligen's Q1 Earnings & Revenues Beat Estimates, Stock Rises
RGEN tops Q1 earnings and revenue estimates, sending shares higher as strong chromatography and analytics business aid growth. The company raises its 2026 EPS view.
Zacks·8d ago
News Placeholder
Repligen Corporation $RGEN Stock Position Decreased by UBS Group AG
UBS Group AG lessened its holdings in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) by 23.8% in the fourth quarter, according to the company in its most recent filing with the Securities...
MarketBeat·8d ago
News Placeholder
Repligen Q1 Earnings Call Highlights
Repligen (NASDAQ:RGEN) reported first-quarter 2026 results that management said reflected broad-based demand across end markets and geographies, alongside margin expansion driven by mix, pricing, and volume leverage. The company also updated full-year guidance to reflect the divestiture of its Polym...
MarketBeat·9d ago
News Placeholder
Repligen (NASDAQ:RGEN) Posts Quarterly Earnings Results, Beats Expectations By $0.10 EPS
Repligen (NASDAQ:RGEN - Get Free Report) issued its earnings results on Tuesday. The biotechnology company reported $0.48 earnings per share for the quarter, topping analysts' consensus estimates of...
MarketBeat·9d ago
News Placeholder
Repligen (RGEN) Q1 Earnings and Revenues Beat Estimates
Repligen (RGEN) delivered earnings and revenue surprises of +24.97% and +1.53%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·9d ago
News Placeholder
Repligen (NASDAQ:RGEN) Updates FY 2026 Earnings Guidance
Repligen (NASDAQ:RGEN) updated its FY 2026 earnings guidance. The company provided EPS guidance of 1.970-2.050 for the period, compared to the consensus estimate of 1.970. The company also issued...
MarketBeat·9d ago
News Placeholder
Repligen Corporation $RGEN Shares Sold by Vanguard Group Inc.
Vanguard Group Inc. lowered its position in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) by 1.0% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,993,945 shares of the biotechnology compa...
MarketBeat·11d ago
News Placeholder
Repligen Corporation $RGEN Holdings Raised by Artemis Investment Management LLP
Artemis Investment Management LLP lifted its stake in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) by 18.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 410,369 shares...
MarketBeat·12d ago
News Placeholder
Repligen Corporation (NASDAQ:RGEN) Given Average Recommendation of "Moderate Buy" by Analysts
Repligen Corporation (NASDAQ:RGEN - Get Free Report) has received a consensus rating of "Moderate Buy" from the fourteen analysts that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendatio...
MarketBeat·12d ago
<
1
2
...
>

Latest RGEN News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.